Background and Clinical Significance of Biomarker-based Patient Enrichment in Non-small-cell Lung Cancer Drug Development

Overview

Journal Sci Rep

Specialty Science

Date 2024 Mar 27

PMID 38531888

Authors

Kenji Harada

Shunsuke Ono

Affiliations

Soon will be listed here.

Abstract

Pharmaceutical companies have adopted biomarker-based enrichment (personalized) strategies to improve research and development productivity. We explored the background in which personalized strategies are adopted and examined whether their adoption is linked to improved efficacy of new drugs approved for non-small cell lung cancer (NSCLC) by US Food and Drug Administration (FDA). We extracted data from the first labels of drugs approved for NSCLC between May 2003 and February 2021, and performed a qualitative comparative analysis and meta-analysis. Personalized strategies were adopted in more than half of the trials (16/27) and were often used in trials aimed at obtaining first-line indications and in drugs that were not first-in-class. The meta-analysis showed that personalized trials had significantly improved progression-free survival (PFS) hazard ratio (HR) than trials without personalization but not for relative response rate ratio (RRR) or overall survival (OS) HR. Trials in which PFS HR was the primary endpoint tended to have improved PFS HR, and trials in which OS HR was the primary endpoint had worse PFS HR. The efficacy endpoints that are substantially affected by personalized strategies appear to differ, especially for new drugs with novel mechanism of action (MOA), because trial designs are employed to validate drug-specific advantages.

Citing Articles

Lung cancer organoid-based drug evaluation models and new drug development application trends.

Lee E, Lee S, Seong Y, Ku B, Cho H, Kim K Transl Lung Cancer Res. 2025; 13(12):3741-3763.

PMID: 39830742 PMC: 11736608. DOI: 10.21037/tlcr-24-603.

References

Mok T, Wu Y, Thongprasert S, Yang C, Chu D, Saijo N . Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361(10):947-57. DOI: 10.1056/NEJMoa0810699. View

Schwaederle M, Zhao M, Lee J, Lazar V, Leyland-Jones B, Schilsky R . Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms: A Meta-analysis. JAMA Oncol. 2016; 2(11):1452-1459. DOI: 10.1001/jamaoncol.2016.2129. View

Inamura K, Takeuchi K, Togashi Y, Nomura K, Ninomiya H, Okui M . EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol. 2008; 3(1):13-7. DOI: 10.1097/JTO.0b013e31815e8b60. View

Schwaederle M, Zhao M, Lee J, Eggermont A, Schilsky R, Mendelsohn J . Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials. J Clin Oncol. 2015; 33(32):3817-25. PMC: 4737863. DOI: 10.1200/JCO.2015.61.5997. View

Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I . EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004; 101(36):13306-11. PMC: 516528. DOI: 10.1073/pnas.0405220101. View

Yu Y, Zeng D, Ou Q, Liu S, Li A, Chen Y . Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis. JAMA Netw Open. 2019; 2(7):e196879. PMC: 6625073. DOI: 10.1001/jamanetworkopen.2019.6879. View

Scannell J, Blanckley A, Boldon H, Warrington B . Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov. 2012; 11(3):191-200. DOI: 10.1038/nrd3681. View

Jameson S, Masopust D . Diversity in T cell memory: an embarrassment of riches. Immunity. 2010; 31(6):859-71. PMC: 2957815. DOI: 10.1016/j.immuni.2009.11.007. View

Jansen C, Prokhnevska N, Master V, Sanda M, Carlisle J, Bilen M . An intra-tumoral niche maintains and differentiates stem-like CD8 T cells. Nature. 2019; 576(7787):465-470. PMC: 7108171. DOI: 10.1038/s41586-019-1836-5. View

10.

Miyamae Y, Shimizu K, Hirato J, Araki T, Tanaka K, Ogawa H . Significance of epidermal growth factor receptor gene mutations in squamous cell lung carcinoma. Oncol Rep. 2011; 25(4):921-8. DOI: 10.3892/or.2011.1182. View

11.

Suda K, Mizuuchi H, Maehara Y, Mitsudomi T . Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation--diversity, ductility, and destiny. Cancer Metastasis Rev. 2012; 31(3-4):807-14. DOI: 10.1007/s10555-012-9391-7. View

12.

Shi H, Moriceau G, Kong X, Lee M, Lee H, Koya R . Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun. 2012; 3:724. PMC: 3530385. DOI: 10.1038/ncomms1727. View

13.

Katayama R, Shaw A, Khan T, Mino-Kenudson M, Solomon B, Halmos B . Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med. 2012; 4(120):120ra17. PMC: 3385512. DOI: 10.1126/scitranslmed.3003316. View

14.

Schuhmacher A, Wilisch L, Kuss M, Kandelbauer A, Hinder M, Gassmann O . R&D efficiency of leading pharmaceutical companies - A 20-year analysis. Drug Discov Today. 2021; 26(8):1784-1789. DOI: 10.1016/j.drudis.2021.05.005. View

15.

Thress K, Paweletz C, Felip E, Cho B, Stetson D, Dougherty B . Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med. 2015; 21(6):560-2. PMC: 4771182. DOI: 10.1038/nm.3854. View

16.

Casaluce F, Sgambato A, Maione P, Rossi A, Ferrara C, Napolitano A . ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC. Target Oncol. 2013; 8(1):55-67. DOI: 10.1007/s11523-012-0250-9. View

17.

Boland J, Erdogan S, Vasmatzis G, Yang P, Tillmans L, Johnson M . Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas. Hum Pathol. 2009; 40(8):1152-8. DOI: 10.1016/j.humpath.2009.01.012. View

18.

Jardim D, Fontes Jardim D, Schwaederle M, Wei C, Lee J, Hong D . Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval. J Natl Cancer Inst. 2015; 107(11). PMC: 4857149. DOI: 10.1093/jnci/djv253. View

19.

Hodi F, Hwu W, Kefford R, Weber J, Daud A, Hamid O . Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. J Clin Oncol. 2016; 34(13):1510-7. PMC: 5070547. DOI: 10.1200/JCO.2015.64.0391. View

20.

Kobayashi S, Boggon T, Dayaram T, Janne P, Kocher O, Meyerson M . EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005; 352(8):786-92. DOI: 10.1056/NEJMoa044238. View